Bruin Biometrics’ Device Shows Promise for Early OA Detection

Bruin Biometrics has reported that its OrthoSonos device is showing promising trends in the detection of early stage osteoarthritis (OA). Initial data show that patients with confirmed severe OA who are scheduled for arthroplasty demonstrate a consistently negative OrthoSonos Health Index (OHI), while patients with healthy joints have a consistently positive OHI. Patients with OA for whom surgery is not yet required reported OHIs trending from healthy to chronic joints.

Martin Burns, CEO of Bruin Biometrics, told OTW, “The study was conducted as an independent UCLA investigator study performed at Harbor-UCLA Medical Center in collaboration with Dr. Louis Kwong as the co-principal investigator. One year from now, Bruin Biometrics anticipates having received approval from both FDA and CE Notified Bodies to market OrthoSonos in European and North American markets.”

“Clinical studies being conducted within the coming year are focused on using the OrthoSonos Health Index to discriminate between failing and well-functioning implants with a high degree of confidence, thereby providing vital information for use by clinicians to inform the current day diagnostic dilemmas surrounding joint failure. Implant manufacturers will be deploying OrthoSonos in support of their quality and post market surveillance initiatives. Bruin Biometrics aims to support the U.S. military’s efforts to detect early stage osteoarthritis via clinical study enabled deployment of OrthoSonos. Patients will benefit most from early detection of accelerated wear and abnormal tribological patterns. This will offer hope to those millions of patients who do not know whether their joints are functioning well or failing.”